Overview
Overview
This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements. Reconstitute: Add 3.0 mL b
- Category
- Growth Hormone
- Routes
- subcutaneous
Mechanism
CJC-1295 NO DAC
Mechanism of action
Mechanism of action
CJC-1295 No DAC is a small change to the body's own growth-hormone-releasing hormone (GHRH). Four edits to the sequence make it last longer than natural GHRH, which only survives a few minutes. The change gives it a half-life of about 30 minutes. Once injected, CJC-1295 No DAC travels to the pituitary gland — a small structure at the base of the brain that controls many hormones. It attaches to GHRH receptors on the pituitary and tells the gland to release growth hormone (GH). Because the compound clears in about 30 minutes, each dose makes one short GH burst, then fades. That pulsatile pattern is closer to how the body normally releases GH in waves, especially during deep sleep. Many planning frameworks favor it over long-acting compounds because the pulse-and-rest pattern may help keep receptors responsive over time. Each GH pulse signals the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 is one of the markers researchers track because it carries many of the downstream effects on tissue, muscle, and metabolism. Ipamorelin is a different kind of GH stimulator. It works through the ghrelin receptor , not the GHRH receptor. Pushing both doors at once usually creates a larger GH pulse than either compound alone. That is why CJC-1295 No DAC + Ipamorelin is one of the most discussed GH-related stack patterns in research planning. Short half-life supports clean, separated GH pulses rather than constant elevation. Selective for GHRH receptors. Does not directly activate the ghrelin pathway. Repeated daily pulses can hold IGF-1 levels higher over time even when each single dose washes out quickly. Insulin from a recent meal can blunt the GH pulse, which is why fasted windows are common in planning.
Key research findings
- 01
Compound identity / foundational pharmacology (in vitro + animal model): According to PubMed, the molecule sold as 'CJC-1295 no DAC' corresponds to modified GRF(1-29) - the tetrasubstituted hGRF(1-29) backbone (substitutions at positions 2, 8, 15, 27) characterized by Jette et al., Endocrinology 2005 (PMID 15817669). That paper identifies the long-acting property of 'CJC-1295 with DAC' as coming specifically from an added maleimidopropionamide that conjugates to serum albumin; in cultured rat anterior pituitary cells (in vitro) the analogs stimulated GH secretion, and in rats (animal model) the albumin-conjugated form persisted in plasma beyond 72 h. The no-DAC form lacks that albumin anchor and is the short-acting GHRH-receptor agonist precursor.
- 02
Modification rationale (human study, parent analog - not the assembled compound): Soule et al., J Clin Endocrinol Metab 1994 (PMID 7962295) showed in 10 healthy men that the D-Ala2 substitution - one of the four modifications present in the no-DAC backbone - reduced metabolic clearance (21 vs 39.7 mL/kg/min) and modestly extended the plasma disappearance half-time of GHRH(1-29)NH2 (about 6.7 vs 4.3 min). This supports the DPP-4-resistance rationale for the modifications but characterizes the parent peptide, not the fully assembled no-DAC compound.
- 03
Substantive pharmacodynamic data belong to the DAC version, not the no-DAC form (human + animal model, contextual): The randomized human data carrying the 'CJC-1295' name used the DAC (albumin-binding) version - dose-dependent multi-day GH and IGF-1 increases with an estimated half-life of ~5.8-8.1 days (Teichman 2006, PMID 16352683), preserved GH pulsatility (Ionescu & Frohman 2006, PMID 17018654), and growth normalization in GHRH-knockout mice (Alba 2006, PMID 16822960). These results are for the longer-acting DAC form and do not transfer directly to the no-DAC compound.
- 04
Most indexed work specific to the no-DAC entity is analytical/forensic, not efficacy-based: Anti-doping and forensic chemistry is the main body of literature that explicitly handles the no-DAC molecule - 'modified GRF 1-29' (including N-terminal glycine-modified variants) identified in seized gray-market material (Gajda 2018, PMID 30136411); a 29-amino-acid C-terminal-amide peptide marketed as 'CJC-1295' (the no-DAC form) identified in an unknown preparation (Henninge 2010, PMID 21204297); and validated LC-MS/MS detection of these GHRH analogs (Memdouh 2021, PMID 34665524; Cristea 2023, PMID 37806509). These confirm structure and gray-market presence but report no efficacy or controlled safety data.
- 05
Regulatory status and absence of dedicated efficacy data: GHRH and its synthetic analogs, including CJC-1295, are on the WADA Prohibited List (class S2), and CJC-1295 / CJC-1295-with-DAC were reviewed by the FDA Pharmacy Compounding Advisory Committee in December 2024, where peptide-aggregation/immunogenicity and manufacturing-sensitivity considerations were raised for compounded products. No dedicated controlled human or animal efficacy or pharmacokinetic study of the no-DAC (modified GRF 1-29) form by that identity was located.
- 06
Evidence maturity per recent reviews (narrative reviews): Multiple 2026 narrative reviews that mention CJC-1295 (often as a CJC-1295 + ipamorelin combination) consistently describe human safety and efficacy data as scarce, report animal-only signals (e.g., improved muscle tetanic tension in a murine glucocorticoid muscle-loss model), and state that indications, dosing, frequency, and duration 'remain unknown' (Mayfield 2026, PMID 41476424; Mendias & Awan 2026, PMID 41966639; Rahman 2026, PMID 41490200). These signals are preclinical and not specific to the no-DAC form.
Primary source: Teichman et al. 2006 (JCEM, Phase 1): CJC-1295 produced sustained GH and IGF-1 elevation in healthy adults with short-term tolerability data. Ionescu and Frohman 2006 (JCEM): Showed that pulsatile GH secretion was preserved during CJC-1295 stimulation. Alba et al. 2006 (preclinical): Daily CJC-1295 in GHRH-knockout mice normalized growth and body-composition markers. Jette et al. 2005 (Endocrinology): Identified CJC-1295 as a long-lasting GRF analog and described its albumin-binding chemistry. ConjuChem Phase 2, 2006 (NCT00267527, DAC version): Halted in HIV patients after a cardiac event. Investigators said the event was unrelated, but the program was discontinued. This trial used the DAC version, not No DAC. What This Means for No DAC
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Supports sustained GH and IGF-1 elevation through pulsatile release patterns[1][2].
Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation[3].
Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models[2].
Protocol Reference
Protocol reference
Commonly cited research range: 100–300 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
100 mcg of each peptide
Weeks 3–4
150 mcg of each peptide
Weeks 5–8
200 mcg of each peptide
Weeks 9–12
200–300 mcg of each peptide
| Phase | Reference amount | Component amounts | Units / volume |
|---|---|---|---|
| Weeks 1–2 | 100 mcg of each peptide | CJC-1295 (no DAC) 100 mcg + Ipamorelin 100 mcg | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg of each peptide | CJC-1295 (no DAC) 150 mcg + Ipamorelin 150 mcg | 4.5 units (0.04 mL) |
| Weeks 5–8 | 200 mcg of each peptide | CJC-1295 (no DAC) 200 mcg + Ipamorelin 200 mcg | 6 units (0.06 mL) |
| Weeks 9–12 | 200–300 mcg of each peptide | CJC-1295 (no DAC) 200–300 mcg + Ipamorelin 200–300 mcg | 6–9 units (0.06–0.09 mL) |
Titration protocol
- Weeks 1–2Start100 mcg of each peptide, once daily
Subcutaneous. Administer on an empty stomach, 2–3 hours after the last meal; most schedules place the draw pre-bed. Leave roughly 20–30 minutes between the injection and eating. Rotate sites between abdomen, thigh, and upper arm.
- Weeks 3–4Build150 mcg of each peptide, once daily
Hold this step for the full two weeks before stepping up. Same fasted window and site rotation as Weeks 1–2.
- Weeks 5–8Build200 mcg of each peptide, once daily
Hold four weeks at this step. Twice-daily schedules split the day into a morning (fasted) draw and a pre-bed draw at the same per-draw amount.
- Weeks 9–12Maintenance200–300 mcg of each peptide, once daily
300 mcg of each peptide (9 units / 0.09 mL) is the ceiling for this ladder — do not exceed it. Standard block runs 8–12 weeks on, then 4 weeks off. Use a fresh sterile insulin syringe for every draw.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Inspect the vial: check label, lot, and appearance — the lyophilized powder should be intact and the vial sealed.
- 02🧴Wipe the stopper with a fresh alcohol prep pad and let it air dry.
- 03💉Draw 1.5 mL bacteriostatic water into a sterile syringe — this 10 mg vial yields 6.67 mg/mL.
- 04💧Inject down the wall: slowly inject the BAC water down the inside wall of the vial; do not spray directly onto the powder, and avoid foaming.
- 05🔄Swirl, do not shake: gently roll or swirl until the powder is fully dissolved.
- 06🏷️Calculate the draw from the dosing table above; use a fresh sterile insulin syringe for each dose.
- 07❄️Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Studied for short-pulse GH stimulation, often combined with ghrelin-receptor secretagogues in research protocols.
Teichman et al. 2006 (JCEM, Phase 1): CJC-1295 produced sustained GH and IGF-1 elevation in healthy adults with short-term tolerability data. Ionescu and Frohman 2006 (JCEM): Showed that pulsatile GH secretion was preserved during CJC-1295 stimulation. Alba et al. 2006 (preclinical): Daily CJC-1295 in GHRH-knockout mice normalized growth and body-composition markers. Jette et al. 2005 (Endocrinology): Identified CJC-1295 as a long-lasting GRF analog and described its albumin-binding chemistry. ConjuChem Phase 2, 2006 (NCT00267527, DAC version): Halted in HIV patients after a cardiac event. Investigators said the event was unrelated, but the program was discontinued. This trial used the DAC version, not No DAC. What This Means for No DAC
- 01Compound identity / foundational pharmacology (in vitro + animal model): According to PubMed, the molecule sold as 'CJC-1295 no DAC' corresponds to modified GRF(1-29) - the tetrasubstituted hGRF(1-29) backbone (substitutions at positions 2, 8, 15, 27) characterized by Jette et al., Endocrinology 2005 (PMID 15817669). That paper identifies the long-acting property of 'CJC-1295 with DAC' as coming specifically from an added maleimidopropionamide that conjugates to serum albumin; in cultured rat anterior pituitary cells (in vitro) the analogs stimulated GH secretion, and in rats (animal model) the albumin-conjugated form persisted in plasma beyond 72 h. The no-DAC form lacks that albumin anchor and is the short-acting GHRH-receptor agonist precursor.
- 02Modification rationale (human study, parent analog - not the assembled compound): Soule et al., J Clin Endocrinol Metab 1994 (PMID 7962295) showed in 10 healthy men that the D-Ala2 substitution - one of the four modifications present in the no-DAC backbone - reduced metabolic clearance (21 vs 39.7 mL/kg/min) and modestly extended the plasma disappearance half-time of GHRH(1-29)NH2 (about 6.7 vs 4.3 min). This supports the DPP-4-resistance rationale for the modifications but characterizes the parent peptide, not the fully assembled no-DAC compound.
- 03Substantive pharmacodynamic data belong to the DAC version, not the no-DAC form (human + animal model, contextual): The randomized human data carrying the 'CJC-1295' name used the DAC (albumin-binding) version - dose-dependent multi-day GH and IGF-1 increases with an estimated half-life of ~5.8-8.1 days (Teichman 2006, PMID 16352683), preserved GH pulsatility (Ionescu & Frohman 2006, PMID 17018654), and growth normalization in GHRH-knockout mice (Alba 2006, PMID 16822960). These results are for the longer-acting DAC form and do not transfer directly to the no-DAC compound.
- 04Most indexed work specific to the no-DAC entity is analytical/forensic, not efficacy-based: Anti-doping and forensic chemistry is the main body of literature that explicitly handles the no-DAC molecule - 'modified GRF 1-29' (including N-terminal glycine-modified variants) identified in seized gray-market material (Gajda 2018, PMID 30136411); a 29-amino-acid C-terminal-amide peptide marketed as 'CJC-1295' (the no-DAC form) identified in an unknown preparation (Henninge 2010, PMID 21204297); and validated LC-MS/MS detection of these GHRH analogs (Memdouh 2021, PMID 34665524; Cristea 2023, PMID 37806509). These confirm structure and gray-market presence but report no efficacy or controlled safety data.
- 05Regulatory status and absence of dedicated efficacy data: GHRH and its synthetic analogs, including CJC-1295, are on the WADA Prohibited List (class S2), and CJC-1295 / CJC-1295-with-DAC were reviewed by the FDA Pharmacy Compounding Advisory Committee in December 2024, where peptide-aggregation/immunogenicity and manufacturing-sensitivity considerations were raised for compounded products. No dedicated controlled human or animal efficacy or pharmacokinetic study of the no-DAC (modified GRF 1-29) form by that identity was located.
- 06Evidence maturity per recent reviews (narrative reviews): Multiple 2026 narrative reviews that mention CJC-1295 (often as a CJC-1295 + ipamorelin combination) consistently describe human safety and efficacy data as scarce, report animal-only signals (e.g., improved muscle tetanic tension in a murine glucocorticoid muscle-loss model), and state that indications, dosing, frequency, and duration 'remain unknown' (Mayfield 2026, PMID 41476424; Mendias & Awan 2026, PMID 41966639; Rahman 2026, PMID 41490200). These signals are preclinical and not specific to the no-DAC form.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to CJC-1295 NO DAC.
- 01Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology and Metabolism (2006)et al. (2006)
- 02Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism (2006)et al. (2006)
- 03Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism (2006)et al. (2006)
- 04Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005)et al. (2005)
- 05Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295 and serum protein changes in normal adults. Growth Hormone & IGF Research (2009)et al. (2009)
- 06Clemmons DR. Long-acting forms of GHRH and growth hormone: effects in normal volunteers and adults with GHD. Hormone Research (2007)et al. (2007)
- 07Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis (2010)et al. (2010)
- 08ClinicalTrials.gov Effect of CJC-1295 on weekly growth hormone and daily IGF-1 release in adults with HIV-associated lipodystrophy (NCT00267527). ClinicalTrials.gov registry (2006)et al. (2006)
- 09Aidsmap (NAM). Lipodystrophy study halted after patient death (CJC-1295 with DAC, Phase 2). aidsmap.com (2006)et al. (2006)
- 10U.S. Food and Drug Administration. FDA-approved drugs database (used to confirm absence of an approved CJC-1295 No DAC product). FDA.gov (2026)et al. (2026)
- 11World Anti-Doping Agency. Prohibited list (S2 peptide hormones, growth factors, related substances, and mimetics). WADA (2026)et al. (2026)
Observed Effects
Observed effects in cited research
Commonly Reported Effects
- Mild flushing or warmth shortly after the injection.
- Headache, usually mild and short-lived.
- Injection-site redness or irritation.
- Mild water retention or puffiness.
- Tingling or numbness in the hands, sometimes linked to higher single doses.
Dose-Dependent Pattern
- Higher single doses tend to produce more flushing and headache without a proportional GH gain. This is part of why most planning frameworks add a second daily dose before they raise the size of a single dose.
Theoretical Long-Term Concerns
- Long-term effects on insulin sensitivity and blood sugar are not well studied for the No DAC variant.
- Long-term IGF-1 elevation has theoretical implications for cell growth, which is one reason cancer history is treated as an exclusion.
- No multi-year human safety data exists for the No DAC version specifically.
The CJC-1295 with DAC Safety Event
- A 2006 Phase 2 trial of CJC-1295 with DAC in HIV patients was halted after a participant had a heart attack. Investigators later said the event was unrelated to the compound, but the program was discontinued. That event is tied to the DAC version , which keeps GH levels elevated for days. No similar signal has been reported for the No DAC variant.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Human evidence is limited to early or small studies. Consult a licensed healthcare professional for any clinical decisions.
- Active cancer or recent cancer history. GH and IGF-1 can affect cell growth, and most planning frameworks exclude this group by default.
- Meaningful cardiovascular disease, especially uncontrolled heart conditions.
- Pregnancy or breastfeeding.
- Significant glucose dysregulation or uncontrolled diabetes, because GH can raise blood sugar.
- Known hypersensitivity to peptide products or to bacteriostatic water (benzyl alcohol).
- Glucocorticoids (steroids) can blunt GH response and may complicate planning.
- Insulin and oral diabetes medications may interact with GH-driven glucose changes.
- Thyroid medication adjustments may be relevant because GH affects thyroid hormone conversion.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| CJC-1295 NO DACthis | A synthetic 29-amino-acid GHRH analog (Modified GRF 1-29) that stimulates natural, pulsatile growth hormone secretion from the pituitary; without a DAC it has a short duration of action. | subcutaneous | Investigational / RUO |
| GHRP-2 | A synthetic hexapeptide that activates the ghrelin/GHS receptor (GHS-R1a) to stimulate dose-dependent growth hormone release; it also mildly engages prolactin and cortisol pathways. | subcutaneous | Investigational / RUO |
| GHRP-6 | A synthetic hexapeptide GH secretagogue that binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and appetite via central ghrelin signaling. | subcutaneous | Investigational / RUO |
| HGH 191AA | Recombinant human growth hormone (somatropin), a 191-amino-acid protein identical to endogenous GH, acting on GH receptors to drive IGF-1 production and influence growth, metabolism, and tissue repair. | subcutaneous | Investigational / RUO |
| IGF-1 LR3 | A modified analog of insulin-like growth factor-1 with reduced binding to IGF-binding proteins, giving a markedly extended half-life and prolonged activation of IGF-1 receptor anabolic signaling. | subcutaneous | Investigational / RUO |
| Cortagen | A synthetic tetrapeptide (Ala-Glu-Asp-Pro) of the Khavinson bioregulator class studied for neuroprotective and neuroregenerative activity, including peripheral nerve repair. | subcutaneous | Investigational / RUO |
| DSIP | A naturally occurring nonapeptide studied for influence on sleep architecture and hypothalamic-pituitary-adrenal (stress-axis) modulation; its precise receptor targets remain incompletely characterized. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
In the research literature, 'CJC-1295 no DAC' refers to modified GRF(1-29): a tetrasubstituted analog of the first 29 residues of growth-hormone-releasing hormone (substitutions at positions 2, 8, 15, and 27) that binds the GHRH receptor on anterior-pituitary cells. 'CJC-1295 with DAC' is the same backbone plus a maleimidopropionamide 'Drug Affinity Complex' that covalently attaches to circulating albumin, greatly extending its circulating life (According to PubMed, Jette 2005, PMID 15817669). The no-DAC form lacks that albumin anchor and is therefore described as short-acting.
No dedicated controlled human trial of the no-DAC modified GRF(1-29) was located in the indexed literature - this is a limited-evidence compound. The randomized human data carrying the CJC-1295 name (multi-day GH/IGF-1 elevation, ~6-8 day half-life) were generated with the DAC version (Teichman 2006, PMID 16352683; Ionescu & Frohman 2006, PMID 17018654), and a separate human study on one component modification (D-Ala2) characterized only the parent GHRH(1-29) analog (Soule 1994, PMID 7962295). This is research context, not medical advice.
Because the no-DAC backbone has no albumin anchor, it is described as short-acting; secondary structural sources report a plasma half-life on the order of roughly 30 minutes, versus under ~10 minutes for unmodified GRF(1-29)/sermorelin and the ~5.8-8.1 days measured in humans for the DAC version (Teichman 2006, PMID 16352683). A dedicated indexed pharmacokinetic study quantifying the no-DAC form's half-life was not identified, so this figure should be treated as approximate and not independently confirmed in peer-reviewed human data.
In the foundational rat work, GHRH(1-29)-albumin conjugates (the DAC line) stimulated GH secretion and persisted in plasma beyond 72 hours, and in cultured rat pituitary cells the analogs activated GH release (Jette 2005, PMID 15817669); growth-normalization studies in GHRH-knockout mice also used the DAC version (Alba 2006, PMID 16822960). 2026 reviews additionally note an animal-only report of improved muscle tetanic tension with a CJC-1295 + ipamorelin combination in a murine model (Mayfield 2026, PMID 41476424), but these findings are preclinical and not specific to the no-DAC form.
Research-reported dosing for this compound is not standardized, and dedicated dosing studies of the no-DAC form are absent from the indexed literature; recent reviews explicitly state that indications, dosing, frequency, and duration 'remain unknown' for this peptide class (Mayfield 2026, PMID 41476424). Research-reported ranges vary across sources; for any dosing question, consult the specific protocol reference being used and note that this is a research compound and not medical guidance.
Dedicated tolerability data for the no-DAC form are not available in the indexed literature. The DAC-version human trial reported no serious adverse reactions over its study window (Teichman 2006, PMID 16352683), but those observations cannot be assumed to transfer to the no-DAC form, and the FDA compounding review (December 2024) flagged peptide-aggregation and immunogenicity considerations for compounded CJC-1295 products. Observed effects in research should be interpreted cautiously given the thin evidence base; this is not medical advice.
GHRH and its synthetic analogs, including CJC-1295, are prohibited in sport by WADA (class S2), and forensic studies have repeatedly identified gray-market 'modified GRF 1-29' / 'CJC-1295' preparations of variable and sometimes altered composition - including N-terminal glycine-modified variants - in seized material (Gajda 2018, PMID 30136411; Henninge 2010, PMID 21204297; Memdouh 2021, PMID 34665524). For research-use-only work this makes independent verification of compound identity and purity a significant research-integrity consideration.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.